Please login to the form below

Not currently logged in
Email:
Password:

Baxter - Halozyme’s HyQ faces delay after FDA data request

Anticipated delay in immune disorder treatment’s approval causes US healthcare company’s shares to drop

The US Food and Drug Administration (FDA) has asked Baxter and Halozyme to provide more information to support their biological licence application (BLA) for the immune disorder treatment HyQ.

Baxter acknowledged this would delay the drug's regulatory review and shares of the US healthcare company dropped 7 per cent following the announcement.

The US regulator raised concerns over the range of data available involving the long-term chronic use of the therapy, which is being developed to treat primary immunodeficiencies.

Primary immunodeficiencies are inherited conditions that occur when part of a person's immune system is missing or works incorrectly. People living with such conditions cannot get rid of germs or protect themselves from new germs in an efficient manner.

Baxter had already released data at the 2012 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual meeting in Orlando to support the long-term use of HyQ.

It is unclear whether the company will be able to use data from a longer-term follow-up of this original trial, or whether a new study will have to be implemented.

Baxter and Halozyme said they will work together to develop further studies to provide the FDA with more information, including a meeting with the agency's Blood Products Advisory Committee to determine what data is required.

HyQ, which is intended to be marketed as HyQvia if approved, is a combination product comprising immune globulin (IG) and recombinant human hyaluronidase.

The therapeutic effect of the treatment is provided by IG, while recombinant human hyaluronidase causes the drug to spread through the body. The hyaluronidase technology is developed through Halozyme's platform, which has been licensed by Baxter.

17th April 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics